Cipher Pharmaceuticals sign contract to distribute CF101 in Canada Can-Fite BioPharma Ltd.

‘We are very excited to enter this contract with Cipher and think that they are the best partner for all of us to penetrate the Canadian marketplace,’ mentioned Pnina Fishman, CEO of Can-Fite. ‘We think that Cipher's commitment to us at this stage, prior to the anticipated publication of our Stage II/III psoriasis trial outcomes, is a strong validation of our advancement efforts to day.’ ‘This transaction deepens our Canadian portfolio with a high-potential, novel treatment choice for two essential indications,’ stated Shawn O'Brien, President & CEO of Cipher.‘The data is now building that medical nourishment might be able to change lives in the lives of patients not merely in HIV but across a wide spectrum of immune-related circumstances,’ stated Flemming Morgan, president of the medical nutrition division of Danone, the Financial Instances reports . Two Compounds Kill Dormant TB, MAY LEAD TO New Drugs, Research Says Researchers identified ‘two substances that can destroy a defense mechanism in the tuberculosis bacterium that allows it to stay dormant in contaminated cells,wednesday in the journal Character ‘ according to a report published, Reuters reports.